Eiry Roberts Sells 2,632 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock


Share on StockTwits

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Eiry Roberts sold 2,632 shares of the company’s stock in a transaction on Friday, January 8th. The stock was sold at an average price of $111.06, for a total transaction of $292,309.92. Following the transaction, the insider now owns 15,845 shares of the company’s stock, valued at approximately $1,759,745.70. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Neurocrine Biosciences stock opened at $108.15 on Thursday. The firm has a market capitalization of $10.10 billion, a P/E ratio of 116.29 and a beta of 1.00. Neurocrine Biosciences, Inc. has a 1-year low of $72.14 and a 1-year high of $136.26. The company’s 50-day moving average is $97.98 and its 200 day moving average is $106.30.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Saturday, November 14th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.73). Neurocrine Biosciences had a net margin of 8.96% and a return on equity of 18.18%. The business had revenue of $258.80 million for the quarter, compared to the consensus estimate of $282.59 million. During the same period in the prior year, the company posted $0.56 EPS. The company’s quarterly revenue was up 16.5% compared to the same quarter last year. On average, equities analysts predict that Neurocrine Biosciences, Inc. will post 1.28 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in NBIX. Congress Asset Management Co. MA bought a new stake in shares of Neurocrine Biosciences during the third quarter worth $73,817,000. Two Sigma Advisers LP lifted its holdings in Neurocrine Biosciences by 1.3% during the 2nd quarter. Two Sigma Advisers LP now owns 728,173 shares of the company’s stock valued at $88,837,000 after buying an additional 9,500 shares in the last quarter. Victory Capital Management Inc. boosted its position in Neurocrine Biosciences by 9.2% in the 3rd quarter. Victory Capital Management Inc. now owns 702,111 shares of the company’s stock valued at $67,516,000 after buying an additional 59,279 shares during the period. ArrowMark Colorado Holdings LLC boosted its position in Neurocrine Biosciences by 8.0% in the 2nd quarter. ArrowMark Colorado Holdings LLC now owns 554,740 shares of the company’s stock valued at $67,678,000 after buying an additional 41,269 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Neurocrine Biosciences by 1.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 470,532 shares of the company’s stock worth $45,247,000 after acquiring an additional 8,050 shares in the last quarter. Institutional investors and hedge funds own 93.23% of the company’s stock.

Several analysts have commented on the stock. Morgan Stanley decreased their price target on shares of Neurocrine Biosciences from $133.00 to $121.00 and set an “overweight” rating on the stock in a research note on Wednesday, December 16th. Mizuho dropped their price target on Neurocrine Biosciences from $132.00 to $117.00 and set a “neutral” rating for the company in a research note on Tuesday, November 10th. Smith Barney Citigroup cut their price target on Neurocrine Biosciences from $149.00 to $138.00 in a report on Tuesday, November 10th. Canaccord Genuity decreased their price objective on Neurocrine Biosciences from $145.00 to $122.00 and set a “buy” rating on the stock in a report on Thursday, November 12th. Finally, Benchmark assumed coverage on shares of Neurocrine Biosciences in a report on Wednesday, September 30th. They issued a “hold” rating for the company. One analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $127.45.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc, a commercial-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of neurological, endocrine, and psychiatric disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) for the treatment of tardive dyskinesia; and ORILISSA, a gonadotropin-releasing hormone antagonist for use in the treatment of endometriosis.

Featured Story: Risk Tolerance

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.